(b) Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs . (c) Downgraded by 1 increment as the outcome is indirect. (d) Unable to assess imprecision as study reported the results as median and IQR. (e) Downgraded by 1 increment due to heterogeneity, I2 =51%. Table 54: Clinical evidence summary: IV iron versus oral iron Outcomes No of Participants (studies) Follow up Quality of the evidence (GRADE) Relative effect Anticipated absolute effects Risk with Oral iron Risk difference with Intravenous iron (95% CI) VERY LOWa, b due to risk of bias, imprecision Peto Odds Ratio (from 100 fewer to 500 more) Treating Heart Failure Chronic Heart Failure NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: Outcomes No of Participants (studies) Follow up Quality of the evidence (GRADE) Relative effect Anticipated absolute effects Risk with Oral iron Risk difference with Intravenous iron (95% CI) Improvement in NYHA class Data on improvement in NYHA has only been extracted where quality of life data is not reported in a trial. VERY LOWa, b,c due to risk of bias, indirectness, imprecision (from 137 fewer to 797 fewer) (a) a Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias . (b) Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs. (c) Downgraded by 1 increment as the outcome is indirect. Chronic Heart Failure Treating Heart Failure NICE 2018. All rights reserved. Subject to Notice of rights. 